Argus
•
Sep 02, 2026
CYTK: Lowering target price to $75.00
Summary
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Biogen Inc.
Sep 03, 2026
•
BIIB
Analyst Report: Alnylam Pharmaceuticals, Inc.
Sep 02, 2026
•
ALNY
ARWR: Lowering target price to $87.00
Sep 02, 2026
•
ARWR
TGTX: Raising target price to $62.00
Sep 02, 2026
•
TGTX
HALO: Lowering target price to $118.00
Sep 02, 2026
•
HALO
